The US Food and Drug Administration last week said it has promoted deputy commissioner Janet Woodcock to chief medical officer, a newly created spot. She will retain her duties as deputy commissioner, the FDA said.
In her dual role, Woodcock will be responsible for scientific and planning-related operations, including organizing, directing, staffing, coordinating, and planning.
The US National Institutes of Health has appointed Alan Krensky to be its first deputy director for the Office of Portfolio Analysis and Strategic Initiatives, or OPASI. Krensky, who will start the job on July 8, will oversee the Office’s position as an “incubator space to address critical research efforts in cross-cutting areas of NIH priorities,” NIH director Elias Zerhouni said in a statement.
OPASI was created to “identify important areas of emerging scientific opportunities or rising public health challenges, and to help accelerate investments in these areas to make sure new ideas have a chance to develop,” according to the NIH.
Krensky comes to OPASI from Stanford University, where he worked at the school of medicine as professor of pediatrics.
The US National Institutes of Health last week named seven new members to its advisory committee:
Catherine Deangelis, editor-in-chief of the Journal of the American Medical Association and fellow at the American Association for the Advancement of Science; Karen Holbrooke, president of Ohio State University and professor of physiology, cell biology, and medicine; Ralph Horwitz, chair of the department of medicine at Stanford University; Mary-Claire King, professor of the American Cancer Society; Alan Leshner, CEO of the American Association for the Advancement of Science and executive publisher of Science; John Nelson, former deputy director of the Utah Department of Health; and Barbara Wolfe, professor of economics, population health sciences, public affairs, and faculty affiliates at the Institute for Research and Poverty at the University of Wisconsin at Madison.